Published in J Clin Psychiatry on July 13, 2010
A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence. Drug Alcohol Depend (2011) 0.92
The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone. Drug Alcohol Depend (2015) 0.87
Long-acting injectable naltrexone for the management of patients with opioid dependence. Subst Abuse (2011) 0.82
Naltrexone extended-release injection: an option for the management of opioid abuse. Subst Abuse Rehabil (2011) 0.81
Baseline characteristics of patients predicting suitability for rapid naltrexone induction. Am J Addict (2015) 0.80
NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale. Contemp Clin Trials (2016) 0.77
The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial. Trials (2016) 0.77
Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexone. Drug Alcohol Depend (2014) 0.77
Predictors of induction onto extended-release naltrexone among unemployed heroin-dependent adults. J Subst Abuse Treat (2017) 0.76
Long-acting Preparations in Substance Abuse Management: A Review and Update. Indian J Psychol Med (2013) 0.75
Effects of incentives for naltrexone adherence on opiate abstinence in heroin-dependent adults. Addiction (2016) 0.75
Factors associated with using opiates while under extended-release naltrexone blockade: A descriptive pilot study. J Subst Abuse Treat (2016) 0.75
Quality of life as an outcome of opioid use disorder treatment: A systematic review. J Subst Abuse Treat (2017) 0.75
A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry (1988) 8.53
A behavioral approach to achieving initial cocaine abstinence. Am J Psychiatry (1991) 3.97
Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry (2006) 3.06
Behavioral family counseling and naltrexone for male opioid-dependent patients. J Consult Clin Psychol (2003) 2.34
Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement. Arch Gen Psychiatry (2001) 2.29
Improvement in naltrexone treatment compliance with contingency management. Drug Alcohol Depend (1999) 2.17
Network therapy for addiction: a model for office practice. Am J Psychiatry (1993) 1.60
Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Psychopharmacology (Berl) (2001) 1.53
Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness? Am J Drug Alcohol Abuse (2006) 1.44
Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review. Addiction (2006) 1.37
Behavioral naltrexone therapy: an integrated treatment for opiate dependence. J Subst Abuse Treat (2002) 1.36
Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: a pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels. Addict Biol (2003) 1.15
Can psychotherapy rescue naltrexone treatment of opioid addiction? NIDA Res Monogr (1995) 1.03
Effects of contingent payment on compliance with a naltrexone regimen. Am J Drug Alcohol Abuse (1979) 0.99
Psychosocial and treatment correlates of opiate free success in a clinical review of a naltrexone implant program. Subst Abuse Treat Prev Policy (2007) 0.97
Betting on change: modeling transitional probabilities to guide therapy development for opioid dependence. Psychol Addict Behav (2009) 0.96
A comparison of oral and implant naltrexone outcomes at 12 months. J Opioid Manag (2007) 0.86
Maintenance treatment with depot opioid antagonists in subcutaneous implants: an alternative in the treatment of opioid dependence. Addict Biol (2003) 0.86
An international consensus for assessing internet gaming disorder using the new DSM-5 approach. Addiction (2014) 8.38
What's in a word? Addiction versus dependence in DSM-V. Am J Psychiatry (2006) 8.22
Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet (2011) 6.35
A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology (2003) 3.66
A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology (2005) 3.53
Preliminary psychometric properties of the Acceptance and Action Questionnaire-II: a revised measure of psychological inflexibility and experiential avoidance. Behav Ther (2011) 3.49
Internet gaming disorder and the DSM-5. Addiction (2013) 3.46
Direct care workers in the National Drug Abuse Treatment Clinical Trials Network: characteristics, opinions, and beliefs. Psychiatr Serv (2007) 3.38
Concurrent naltrexone and prolonged exposure therapy for patients with comorbid alcohol dependence and PTSD: a randomized clinical trial. JAMA (2013) 3.25
Decreased gray matter concentration in the insular, orbitofrontal, cingulate, and temporal cortices of cocaine patients. Biol Psychiatry (2002) 3.22
Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry (2006) 3.06
DSM-5 criteria for substance use disorders: recommendations and rationale. Am J Psychiatry (2013) 2.89
Effectiveness of HIV/STD sexual risk reduction groups for women in substance abuse treatment programs: results of NIDA Clinical Trials Network Trial. J Acquir Immune Defic Syndr (2008) 2.78
Limbic activation to cigarette smoking cues independent of nicotine withdrawal: a perfusion fMRI study. Neuropsychopharmacology (2007) 2.73
Cognitive deficits predict low treatment retention in cocaine dependent patients. Drug Alcohol Depend (2005) 2.66
Changes in the prevalence of non-medical prescription drug use and drug use disorders in the United States: 1991-1992 and 2001-2002. Drug Alcohol Depend (2007) 2.63
Acute effect of methadone maintenance dose on brain FMRI response to heroin-related cues. Am J Psychiatry (2007) 2.60
Abuse liability measures for use in analgesic clinical trials in patients with pain: IMMPACT recommendations. Pain (2013) 2.58
The status of disulfiram: a half of a century later. J Clin Psychopharmacol (2006) 2.48
Issues for DSM-V: should obesity be included as a brain disorder? Am J Psychiatry (2007) 2.48
Do treatment improvements in PTSD severity affect substance use outcomes? A secondary analysis from a randomized clinical trial in NIDA's Clinical Trials Network. Am J Psychiatry (2009) 2.44
A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry (2010) 2.34
Imaging dopamine transmission in cocaine dependence: link between neurochemistry and response to treatment. Am J Psychiatry (2011) 2.29
Multisite randomized trial of behavioral interventions for women with co-occurring PTSD and substance use disorders. J Consult Clin Psychol (2009) 2.26
Organizational Readiness for Change and opinions toward treatment innovations. J Subst Abuse Treat (2007) 2.14
Prelude to passion: limbic activation by "unseen" drug and sexual cues. PLoS One (2008) 2.07
The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking. J Clin Psychopharmacol (2006) 2.00
Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations. Pain (2013) 1.89
Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend (2012) 1.85
Drug treatment as HIV prevention: a research update. J Acquir Immune Defic Syndr (2010) 1.79
A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend (2004) 1.75
Pharmacogenetic approaches to the treatment of alcohol addiction. Nat Rev Neurosci (2011) 1.74
Cognition, commitment language, and behavioral change among cocaine-dependent patients. Psychol Addict Behav (2008) 1.72
Menstrual cycle phase at quit date predicts smoking status in an NRT treatment trial: a retrospective analysis. J Womens Health (Larchmt) (2008) 1.67
Treatment programs in the National Drug Abuse Treatment Clinical Trials Network. Drug Alcohol Depend (2007) 1.64
Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addiction (2013) 1.63
Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. J Subst Abuse Treat (2006) 1.63
Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend (2011) 1.62
Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial. Addiction (2012) 1.59
Smoking cessation treatment in community-based substance abuse rehabilitation programs. J Subst Abuse Treat (2007) 1.57
Comparing attentional bias to smoking cues in current smokers, former smokers, and non-smokers using a dot-probe task. Drug Alcohol Depend (2002) 1.56
Genomewide suggestive linkage of opioid dependence to chromosome 14q. Hum Mol Genet (2007) 1.54
Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology (Berl) (2007) 1.53
Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers. Neuropsychopharmacology (2007) 1.53
Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend (2003) 1.50
Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain (2007) 1.48
Comparison of smoked marijuana and oral Delta(9)-tetrahydrocannabinol in humans. Psychopharmacology (Berl) (2002) 1.47
Effects of varenicline on smoking cue–triggered neural and craving responses. Arch Gen Psychiatry (2011) 1.45
Zero-inflated and hurdle models of count data with extra zeros: examples from an HIV-risk reduction intervention trial. Am J Drug Alcohol Abuse (2011) 1.44
Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness? Am J Drug Alcohol Abuse (2006) 1.44
Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep. J Acquir Immune Defic Syndr (2007) 1.44
Cocaine withdrawal severity and urine toxicology results from treatment entry predict outcome in medication trials for cocaine dependence. Addict Behav (2002) 1.44
Internet-delivered treatment for substance abuse: a multisite randomized controlled trial. Am J Psychiatry (2014) 1.40
Priority actions to improve the care of persons with co-occurring substance abuse and other mental disorders: a call to action. Biol Psychiatry (2004) 1.39
Design and methodological considerations of an effectiveness trial of a computer-assisted intervention: an example from the NIDA Clinical Trials Network. Contemp Clin Trials (2011) 1.38
Modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend (2011) 1.38
Retrospective study: influence of menstrual cycle on cue-induced cigarette craving. Nicotine Tob Res (2004) 1.37
Sustained-release naltrexone: novel treatment for opioid dependence. Expert Opin Investig Drugs (2007) 1.37
Behavioral naltrexone therapy: an integrated treatment for opiate dependence. J Subst Abuse Treat (2002) 1.36
Naltrexone for heroin dependence treatment in St. Petersburg, Russia. J Subst Abuse Treat (2004) 1.35
Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants. Drug Alcohol Depend (2005) 1.33
Current status of co-occurring mood and substance use disorders: a new therapeutic target. Am J Psychiatry (2013) 1.33
A randomized placebo-controlled trial of gabapentin for cocaine dependence. Drug Alcohol Depend (2005) 1.31
DAT genotype modulates brain and behavioral responses elicited by cigarette cues. Neuropsychopharmacology (2008) 1.31
The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study. Drug Alcohol Depend (2009) 1.30
The impact of trauma-focused group therapy upon HIV sexual risk behaviors in the NIDA Clinical Trials Network "Women and trauma" multi-site study. AIDS Behav (2009) 1.28
Acute physiological and behavioral effects of intranasal methamphetamine in humans. Neuropsychopharmacology (2007) 1.26
A genetic association study of the mu opioid receptor and severe opioid dependence. Psychiatr Genet (2003) 1.25
Generalizability of clinical trials for alcohol dependence to community samples. Drug Alcohol Depend (2008) 1.25
Reinforcing effects of oral Delta9-THC in male marijuana smokers in a laboratory choice procedure. Psychopharmacology (Berl) (2005) 1.18
Extended-release mixed amphetamine salts and topiramate for cocaine dependence: a randomized controlled trial. Biol Psychiatry (2012) 1.18
Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend (2005) 1.18
Gender differences with high-dose naltrexone in patients with co-occurring cocaine and alcohol dependence. J Subst Abuse Treat (2007) 1.18
A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms. Drug Alcohol Depend (2006) 1.17
Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction (2010) 1.16
Treatment of depression in patients with opiate dependence. Biol Psychiatry (2004) 1.16
Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin. Psychopharmacology (Berl) (2006) 1.16
Dopamine transporter genotype modulation of neural responses to smoking cues: confirmation in a new cohort. Addict Biol (2011) 1.16
A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention. Alcohol Clin Exp Res (2008) 1.15
Treatment of patients with substance use disorders, second edition. American Psychiatric Association. Am J Psychiatry (2007) 1.14
Generalizability of clinical trial results for major depression to community samples: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry (2008) 1.13
Comparison of the analgesic effects of dronabinol and smoked marijuana in daily marijuana smokers. Neuropsychopharmacology (2013) 1.13
Predictors of retention in naltrexone maintenance for opioid dependence: analysis of a stage I trial. Am J Addict (2006) 1.11
A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addict Behav (2007) 1.11
Management of relapse in naltrexone maintenance for heroin dependence. Drug Alcohol Depend (2007) 1.11
Alcohol potentiates hepatitis C virus replicon expression. Hepatology (2003) 1.11
A double-blind, placebo-controlled trial of modafinil for cocaine dependence. J Subst Abuse Treat (2012) 1.10
Interaction between naltrexone and oral THC in heavy marijuana smokers. Psychopharmacology (Berl) (2002) 1.10
Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders. J Am Acad Child Adolesc Psychiatry (2011) 1.10